Tesla shares surged as the company announced plans to implement its Full Self-Driving (FSD) system in the EU and China by early 2025. However, regulatory challenges in the EU, including the new DCAS framework, are expected to limit Tesla's FSD capabilities and adoption in the region.
Tesla’s FSD Plans for EU and China in 2025 Face Regulatory Setbacks Under New DCAS Rules
On September 5, Tesla shares surged after the company announced an ambitious FSD implementation plan in the EU and China during the first quarter of 2025. However, Tesla's exponentially increasing FSD-related capabilities are about to encounter substantial regulatory inertia, which will likely restrict the EV giant's potential for growth.
Tesla has recently disclosed its roadmap for releasing its FSD in the forthcoming months. The concurrent unlocking of the ability to reverse in FSD and the advent of FSD version 13 in October are noteworthy. This serves as a testament to Tesla's increasing computing capacity, which is currently facilitating the rapid implementation of improved capabilities.
Of course, the critical development is the implementation of FSD in the EU and China in Q1 2025. As a result, Tesla has experienced a roughly six percent increase in early morning trading. Additionally, approximately $31 million in net call premium has been exchanged.
However, Tesla is confronted with regulatory obstacles in the EU. It has recently implemented the UN-led Driver Control Assistance Systems (DCAS) regulations despite its aspirations to implement the most recent FSD capabilities. According to Wccftech, this is a critical issue, as the DCAS framework's phase 1, anticipated to be implemented in January 2025, does not permit autonomous driving.
"To avoid driver overreliance on such systems, the regulation stipulates that DCAS shall be designed to ensure that the driver remains engaged with the driving task. The driver’s hands must remain on the wheel and the system shall monitor the driver’s visual engagement with the road, triggering alarms after 5 seconds when it detects that this is no longer the case."
Tesla’s FSD Rollout in EU Faces Limitations, While China Offers a More Favorable Market
Naturally, negotiations regarding the second phase of the DCAS are still in progress, with the subsequent workshop scheduled for September 9. As a result, it is more probable that Tesla will introduce a degraded version of the FSD in the EU during Q1 2025, which is likely to restrict its adoption.
Remember that, as per Gary Black of Future Fund, Tesla's earnings per share (EPS) increase by $0.05 per share for each 5 percent increase in FSD adoption.
Conversely, Tesla is anticipated to encounter a significantly more favorable environment in China, where Mercedes has recently been granted formal sanction to commence testing its proprietary Level 4 Advanced Driver Assistance System (ADAS). This system enables autonomous driving for extended periods without human supervision. In contrast, Tesla's FSD is classified as a Level 2 currency.


Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
Samsung Set to Begin HBM4 Production for Nvidia and AMD
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Rewardy Wallet Integrates 1inch Swap API to Enable Gasless, Optimized Token Swaps
The Maire - EuroChem Case: Three Lessons for Global Business
Google Disrupts Major Residential Proxy Network IPIDEA
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
ASML’s EUV Monopoly Powers the Global AI Chip Boom
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 



